SpaceX Going Public Is Not a Reason to Abandon Rocket Lab

Rocket Lab highlights momentum with Q1 revenue up 63.5% YoY to $200.3M and backlog rising 20.2% sequentially to $2.2B, alongside 31 new Electron/HASTE contracts and >70 contracted launches. The company guides Q2 revenue to $225M–$240M (up 16% sequentially at the midpoint) and signed a $190M HASTE contract for 20 hypersonic test flights. However, Neutron’s first launch target was pushed to Q4 2026 after a development setback and Rocket Lab remains unprofitable (Q1 net loss $45M; expected adjusted EBITDA loss of $20M–$26M in Q2), while customer and fixed-price U.S. government exposure remain concentrated.

Analysis

The immediate market reaction is likely to overrate the "space basket" effect and underweight the actual economics. Passive flow into the new public-space name looks too small to matter, so the better read-through is that capital will rotate toward the few operators with real revenue visibility and defense adjacency; among those, RKLB’s cleaner defense cadence likely screens better than pure launch peers because government testing demand is less price-sensitive than commercial satellite launches.

The bigger second-order issue is that backlog is not the same as cash conversion when the revenue mix is fixed-price and customer concentration is high. That makes RKLB a story about execution and margin discipline over the next 1-3 quarters, not a simple backlog-to-multiple rerate; any delay on Neutron or slippage in contract conversion would hit sentiment faster than revenue. In contrast, KTOS should benefit from the same hypersonic-testing buildout with less binary development risk, so defense capital may migrate there if investors want exposure without launch-vehicle timing risk.

The Iridium angle is the real optionality, but it cuts both ways: if RKLB can close it at a rational price, the market may start valuing the company on recurring connectivity and not just launch services. If the deal stalls or requires too much equity, the equity story shifts back to dilution and capex pressure, which would likely compress the multiple despite headline growth. The consensus may be missing that the best outcome is not simply "bigger TAM"; it is whether RKLB can turn a launch-heavy model into something with durable recurring gross profit and lower customer concentration over 6-18 months.

Key Decisions for Investors

• Long KTOS / short RKLB on a 1-3 month horizon as a relative-value expression of hypersonic/DoD demand with less development-risk beta; thesis breaks if RKLB reaccelerates Neutron milestones or closes IRDM on favorable terms.
• Buy RKLB only on pullbacks and preferably via 12-18 month call spreads rather than outright equity; this captures Neutron/defense upside while limiting downside from launch delays, dilution, or a margin miss.
• Treat IRDM as event-driven optionality, not a core fundamental long: buy only if the stock lags any credible acquisition chatter and the implied deal premium remains modest; exit if rumor fades and no term sheet emerges within 4-8 weeks.
• Fade any sympathy bid in SPCX/NDAQ-linked space exposure if it is driven purely by headline flow; the passive inclusion effect appears too small to support a durable rerate.
• Set a hard watchpoint on RKLB’s next two quarters: any further Neutron delay or gross-margin compression should be treated as a thesis violation and a signal to reduce exposure.